Exogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptors

Current Medicinal Chemistry

Volumn 21, Issue 9, 2014, Pages 1129-1145

  Albini, A ^a   Rosano, C ^b   Angelini, G ^b   Amaro, A ^b   Esposito, A I ^b   Maramotti, S ^a   Noonan, D M ^c,d   Pfeffer, U ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

Breast cancer; Estrogen receptor alpha; Estrogen receptor beta; Estrogen signaling; Phytoestrogens; Selective estrogen receptor modulators; Xenoestrogens

Indexed keywords

ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; XENOESTROGEN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST DEVELOPMENT; CANCER CELL; CANCER RISK; CELL PROLIFERATION; EMBRYO DEVELOPMENT; HEALTH HAZARD; HORMONAL REGULATION; HUMAN; LIGAND BINDING; MAMMARY GLAND; MATURATION; MENOPAUSE; PLANT; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BREAST NEOPLASMS; ENDOCRINE DISRUPTORS; HUMANS; PHYTOESTROGENS; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84896367648     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131129124640     Document Type: Article

References (204)

1. Beatson, G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet, 1896, 148, 162-165.
2. Jensen E. V., Jacobsonk, H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res., 1962, 18, 387-414.
3. Walter, P.; Green, S.; Greene, G.; Krust, A.; Bornert, J. M.; Jeltsch, J. M.; Staub, A.; Jensen, E.; Scrace, G.; Waterfield, M.; Chambon, P. Cloning of the human estrogen receptor cDNA. Proc. Natl. Acad. Sci. U S A, 1985, 82(23), 23-7893.
4. Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U S A, 1996, 93(12), 12-5930.
5. Kuiper, G. G.; Lemmen, J. G.; Carlsson, B.; Corton, J. C.; Safe, S. H.; van der Saag, P. T.; van der Burg, B.; Gustafsson, J. A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 1998, 139(10), 10-4263.
6. Hahlbrock, Flavonoids in The biochemistry of plants: a comprehensive treatise-secondary plant products. 1981, Vol. 7, pp. 425-456.
7. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389(6652), 6652-758.
8. Patisaul, H. B.; Jefferson, W. The pros and cons of phytoestrogens. Front. Neuroendocrinol., 2010, 31(4), 4-419.
9. This, P.; de Cremoux, P.; Leclercq, G.; Jacquot, Y. A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas, 2011, 70(3), 3-226.
10. Pilsakova, L.; Riecansky, I.; Jagla, F. The physiological actions of isoflavone phytoestrogens. Physiol. Res., 2010, 59(5), 5-664.
11. Makela, S.; Santti, R.; Salo, L.; McLachlan, J. A. Phytoestrogens are partial estrogen agonists in the adult male mouse. Environ. Health Perspect., 1995, 103(7), 7-127.
12. Setchell, K. D.; Zimmer-Nechemias, L.; Cai, J.; Heubi, J. E. Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet, 1997, 350(9070), 9070-27.
13. Dorea, J. G. Maternal xenoestrogen exposure and breast feeding. J. Perinatol., 2005, 25(8), 8-559.
14. Massart, F.; Harrell, J. C.; Federico, G.; Saggese, G. Human breast milk and xenoestrogen exposure: a possible impact on human health. J. Perinatol., 2005, 25(4), 4-288.
15. Low, Y. L.; Taylor, J. I.; Grace, P. B.; Dowsett, M.; Scollen, S.; Dunning, A. M.; Mulligan, A. A.; Welch, A. A.; Luben, R. N.; Khaw, K. T.; Day, N. E.; Wareham, N. J.; Bingham, S. A. Phytoestrogen exposure correlation with plasma estradiol in postmenopausal women in European Prospective Investigation of Cancer and Nutrition-Norfolk may involve diet-gene interactions. Cancer Epidemiol. Biomarkers Prev., 2005, 14(1), 1-220.
16. Grace, P. B.; Taylor, J. I.; Low, Y. L.; Luben, R. N.; Mulligan, A. A.; Botting, N. P.; Dowsett, M.; Welch, A. A.; Khaw, K. T.; Wareham, N. J.; Day, N. E.; Bingham, S. A. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol. Biomarkers Prev., 2004, 13(5), 5-708.
17. Adlercreutz, H.; Fotsis, T.; Bannwart, C.; Wahala, K.; Makela, T.; Brunow, G.; Hase, T. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J. Steroid Biochem., 1986, 25(5B), 791-797. (Pubitemid 17227959)
18. Rice, S.; Whitehead, S. A. Phytoestrogens and breast cancer-promoters or protectors? Endocr. Relat. Cancer, 2006, 13(4), 4-1015.
19. Messina, M. J.; Persky, V.; Setchell, K. D.; Barnes, S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer, 1994, 21(2), 2-131.
20. Handayani, R.; Rice, L.; Cui, Y.; Medrano, T. A.; Samedi, V. G.; Baker, H. V.; Szabo, N. J.; Shiverick, K. T. Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J. Nutr., 2006, 136(1), 1-82.
21. Cotterchio, M.; Boucher, B. A.; Kreiger, N.; Mills, C. A.; Thompson, L. U. Dietary phytoestrogen intake-lignans and isoflavones- and breast cancer risk (Canada). Cancer Causes Control, 2008, 19(3), 3-272.
22. Linseisen, J.; Piller, R.; Hermann, S.; Chang-Claude, J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int. J. Cancer, 2004, 110(2), 2-290.
23. Thanos, J.; Cotterchio, M.; Boucher, B. A.; Kreiger, N.; Thompson, L. U. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control, 2006, 17(10), 10-1261.
24. Cotterchio, M.; Boucher, B. A.; Manno, M.; Gallinger, S.; Okey, A.; Harper, P. Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J. Nutr., 2006, 136(12), 12-3053.
25. Hartman, J.; Strom, A.; Gustafsson, J. A. Current concepts and significance of estrogen receptor beta in prostate cancer. Steroids, 2012, 77(12), 12-1266.
26. Urpi-Sarda, M.; Morand, C.; Besson, C.; Kraft, G.; Viala, D.; Scalbert, A.; Besle, J. M.; Manach, C. Tissue distribution of isoflavones in ewes after consumption of red clover silage. Arch. Biochem. Biophys., 2008, 476(2), 2-210.
27. Ferrari, A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J. Obstet. Gynaecol. Res., 2009, 35(6), 6-1090.
28. Geller, S. E.; Shulman, L. P.; van Breemen, R. B.; Banuvar, S.; Zhou, Y.; Epstein, G.; Hedayat, S.; Nikolic, D.; Krause, E. C.; Piersen, C. E.; Bolton, J. L.; Pauli, G. F.; Farnsworth, N. R. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause, 2009, 16(6), 6-1166.
29. Zand, R. S.; Jenkins, D. J.; Diamandis, E. P. Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res. Treat., 2000, 62(1), 1-49.
30. Rabiau, N.; Trraf, H. K.; Adjakly, M.; Bosviel, R.; Guy, L.; Fontana, L.; Bignon, Y. J.; Bernard-Gallon, D. J. miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo, 2011, 25(6), 6-921.
31. Li, Y.; Sarkar, F. H. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett., 2002, 186(2), 2-164.
32. Richter, D. U.; Abarzua, S.; Chrobak, M.; Scholz, C.; Kuhn, C.; Schulze, S.; Kupka, M. S.; Friese, K.; Briese, V.; Piechulla, B.; Jeschke, U. Effects of phytoestrogen extracts isolated from flax on estradiol production and ER/PR expression in MCF7 breast cancer cells. Anticancer Res., 2010, 30(5), 5-1699.
33. Lee, Y. J.; Jin, Y. R.; Lim, W. C.; Park, W. K.; Cho, J. Y.; Jang, S.; Lee, S. K. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch. Pharm. Res., 2003, 26(1), 1-63.
34. Gallo, D.; Ferlini, C.; Fabrizi, M.; Prislei, S.; Scambia, G. Lack of stimulatory activity of a phytoestrogen-containing soy extract on the growth of breast cancer tumors in mice. Carcinogenesis, 2006, 27(7), 7-1409.
35. Ren, L.; Marquardt, M. A.; Lech, J. J. Estrogenic effects of nonylphenol on pS2, ER and MUC1 gene expression in human breast cancer cells-MCF-7. Chem. Biol. Interact., 1997, 104(1), 1-64.
36. Shiizaki, K.; Goto, K.; Ishige, A.; Komatsu, Y. Bioassay of phytoestrogen in herbal medicine used for postmenopausal disorder using transformed MCF-7 cells. Phytother. Res., 1999, 13(6), 6-503.
37. Bachmeier, B. E.; Mirisola, V.; Romeo, F.; Generoso, L.; Esposito, A.; Dell'eva, R.; Blengio, F.; Killian, P. H.; Albini, A.; Pfeffer, U. Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin. Cell. Physiol. Biochem., 2010, 26(3), 3-482.
38. Sonnenschein, C.; Soto, A. M. An updated review of environmental estrogen and androgen mimics and antagonists. J. Steroid. Biochem. Mol. Biol., 1998, 65(1-6), 143-150. (Pubitemid 28335600)
39. Diamanti-Kandarakis, E.; Bourguignon, J. P.; Giudice, L. C.; Hauser, R.; Prins, G. S.; Soto, A. M.; Zoeller, R. T.; Gore, A. C. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev., 2009, 30(4), 4-342.
40. Watson, C. S.; Bulayeva, N. N.; Wozniak, A. L.; Alyea, R. A. Xenoestrogens are potent activators of nongenomic estrogenic responses. Steroids, 2007, 72(2), 2-134.
41. Maradonna, F.; Batti, S.; Marino, M.; Mita, D. G.; Carnevali, O. Tamoxifen as an emerging endocrine disruptor. effects on fish reproduction and detoxification target genes. Ann. N. Y. Acad. Sci., 2009, 1163, 457-459.
42. Yu, S. J.; Keenan, S. M.; Tong, W.; Welsh, W. J. Influence of the structural diversity of data sets on the statistical quality of three-dimensional quantitative structure-activity relationship (3D-QSAR) models: predicting the estrogenic activity of xenoestrogens. Chem. Res. Toxicol., 2002, 15(10), 10-1234.
43. Frye, C. A.; Bo, E.; Calamandrei, G.; Calza, L.; Dessi-Fulgheri, F.; Fernandez, M.; Fusani, L.; Kah, O.; Kajta, M.; Le Page, Y.; Patisaul, H. B.; Venerosi, A.; Wojtowicz, A. K.; Panzica, G. C. Endocrine disrupters: a review of some sources, effects, and mechanisms of actions on behaviour and neuroendocrine systems. J. Neuroendocrinol., 2012, 24(1), 1-159.
44. Di Vall, S. A. The influence of endocrine disruptors on growth and development of children. Curr. Opin. Endocrinol. Diabetes Obes., 2013, 20(1), 1-55.
45. Yeung, B. H.; Wan, H. T.; Law, A. Y.; Wong, C. K., Endocrine disrupting chemicals: Multiple effects on testicular signaling and spermatogenesis. Spermatogenesis, 2011, 1(3), 3-239.
46. Fowler, P. A.; Bellingham, M.; Sinclair, K. D.; Evans, N. P.; Pocar, P.; Fischer, B.; Schaedlich, K.; Schmidt, J. S.; Amezaga, M. R.; Bhattacharya, S.; Rhind, S. M.; O'Shaughnessy, P. J. Impact of endocrine-disrupting compounds (EDCs) on female reproductive health. Mol. Cell. Endocrinol., 2012, 355(2), 2-239.
47. Guzman, C.; Zambrano, E. [Endocrine disruptor compounds and their role in the developmental programming of the reproductive axis]. Rev. Invest. Clin., 2007, 59(1), 1-81.
48. Rogers, J. A.; Metz, L.; Yong, V. W. Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. Mol. Immunol., 2013, 53(4), 4-430.
49. Caserta, D.; Bordi, G.; Ciardo, F.; Marci, R.; La Rocca, C.; Tait, S.; Bergamasco, B.; Stecca, L.; Mantovani, A.; Guerranti, C.; Fanello, E. L.; Perra, G.; Borghini, F.; Focardi, S. E.; Moscarini, M. The influence of endocrine disruptors in a selected population of infertile women. Gynecol. Endocrinol., 2013, 29, 444-447.
50. Choi, J. S.; Oh, J. H.; Park, H. J.; Choi, M. S.; Park, S. M.; Kang, S. J.; Oh, M. J.; Kim, S. J.; Hwang, S. Y.; Yoon, S. miRNA regulation of cytotoxic effects in mouse Sertoli cells exposed to nonylphenol. Reprod. Biol. Endocrinol., 2011, 9, 126.
51. Cheshenko, K.; Pakdel, F.; Segner, H.; Kah, O.; Eggen, R. I. Interference of endocrine disrupting chemicals with aromatase CYP19 expression or activity, and consequences for reproduction of teleost fish. Gen. Comp. Endocrinol., 2008, 155(1), 1-62.
52. Bainy, A. C. Nuclear receptors and susceptibility to chemical exposure in aquatic organisms. Environ. Int., 2007, 33(4), 4-575.
53. Zmuda, J. M.; Modugno, F.; Weissfeld, J. L.; Cauley, J. A.; Trump, D. L.; Moffett, S. P.; Ferrell, R. E. Peroxisome proliferatoractivated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction. Oncology, 2006, 70(3), 3-189.
54. DES banned again. Nature, 1973, 243(5401), 5401.
55. Dodds, E. C.; G. L.; Lawson, W.; Robinson, R. Oestrogenic activity of certain synthetic compounds. Nature, 1938, 141, 247-248.
56. Lopez-Espinosa, M. J.; Silva, E.; Granada, A.; Molina-Molina, J. M.; Fernandez, M. F.; Aguilar-Garduno, C.; Olea-Serrano, F.; Kortenkamp, A.; Olea, N. Assessment of the total effective xenoestrogen burden in extracts of human placentas. Biomarkers, 2009, 14(5), 5-277.
57. Caserta, D.; Maranghi, L.; Mantovani, A.; Marci, R.; Maranghi, F.; Moscarini, M. Impact of endocrine disruptor chemicals in gynaecology. Hum. Reprod. Update, 2008, 14(1), 1-72.
58. Crain, D. A.; Janssen, S. J.; Edwards, T. M.; Heindel, J.; Ho, S. M.; Hunt, P.; Iguchi, T.; Juul, A.; McLachlan, J. A.; Schwartz, J.; Skakkebaek, N.; Soto, A. M.; Swan, S.; Walker, C.; Woodruff, T. K.; Woodruff, T. J.; Giudice, L. C.; Guillette, L. J., Jr. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil. Steril., 2008, 90(4), 4-940.
59. Hoover, R. N.; Hyer, M.; Pfeiffer, R. M.; Adam, E.; Bond, B.; Cheville, A. L.; Colton, T.; Hartge, P.; Hatch, E. E.; Herbst, A. L.; Karlan, B. Y.; Kaufman, R.; Noller, K. L.; Palmer, J. R.; Robboy, S. J.; Saal, R. C.; Strohsnitter, W.; Titus-Ernstoff, L.; Troisi, R. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N. Engl. J. Med., 2011, 365(14), 14-1314.
60. Moral, R.; Wang, R.; Russo, I. H.; Lamartiniere, C. A.; Pereira, J.; Russo, J. Effect of prenatal exposure to the endocrine disruptor bisphenol A on mammary gland morphology and gene expression signature. J. Endocrinol., 2008, 196(1), 1-112.
61. Bitman, J.; Cecil, H. C.; Harris, S. J.; Fries, G. F. Estrogenic activity of o, p'-DDT in the mammalian uterus and avian oviduct. Science, 1968, 162(3851), 3851-372.
62. Schettler, T. Human exposure to phthalates via consumer products. Int. J. Androl., 2006, 29(1), 1-139.
63. Sharman, M.; Read, W. A.; Castle, L.; Gilbert, J. Levels of di-(2-ethylhexyl) phthalate and total phthalate esters in milk, cream, butter and cheese. Food Addit. Contam., 1994, 11(3), 3-385.
64. Petersen, J. H.; Jensen, L. K. Phthalates and food-contact materials: enforcing the 2008 European Union plastics legislation. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess, 2010, 27(11), 11-1616.
65. Kappenstein, O.; Vieth, B.; Luch, A.; Pfaff, K. Toxicologically relevant phthalates in food. EXS, 2012, 101, 87-106.
66. Xu, Q.; Yin, X.; Wang, M.; Wang, H.; Zhang, N.; Shen, Y.; Xu, S.; Zhang, L.; Gu, Z. Analysis of Phthalate Migration from Plastic Containers to Packaged Cooking Oil and Mineral Water. J. Agric. Food Chem., 2010 Oct. 15. [Epub ahead of print].
67. Rothenbacher, T.; Schwack, W. Rapid identification of additives in poly (vinyl chloride) lid gaskets by direct analysis in real time ionisation and single-quadrupole mass spectrometry. Rapid Commun. Mass Spectrom., 2010, 24(1), 1-29.
68. Gartner, S.; Balski, M.; Koch, M.; Nehls, I. Analysis and migration of phthalates in infant food packed in recycled paperboard. J. Agric. Food Chem., 2009, 57(22), 22-10681.
69. Fromme, H.; Lahrz, T.; Piloty, M.; Gebhart, H.; Oddoy, A.; Ruden, H. Occurrence of phthalates and musk fragrances in indoor air and dust from apartments and kindergartens in Berlin (Germany). Indoor Air, 2004, 14(3), 3-195.
70. Tsumura, Y.; Ishimitsu, S.; Kaihara, A.; Yoshii, K.; Nakamura, Y.; Tonogai, Y. Di (2-ethylhexyl) phthalate contamination of retail packed lunches caused by PVC gloves used in the preparation of foods. Food Addit. Contam., 2001, 18(6), 6-579.
71. Petersen, J. H.; Breindahl, T. Plasticizers in total diet samples, baby food and infant formulae. Food Addit. Contam., 2000, 17(2), 2-141.
72. Aurela, B.; Kulmala, H.; Soderhjelm, L. Phthalates in paper and board packaging and their migration into Tenax and sugar. Food Addit. Contam., 1999, 16(12), 12-577.
73. Olea, N.; Pazos, P.; Exposito, J. Inadvertent exposure to xenoestrogens. Eur. J. Cancer Prev., 1998, 7(1), S17-S23. (Pubitemid 28137720)
74. Olea, N.; Olea-Serrano, F.; Lardelli-Claret, P.; Rivas, A.; Barba-Navarro, A. Inadvertent exposure to xenoestrogens in children. Toxicol. Ind. Health., 1999, 15(1-2), 151-158. (Pubitemid 30484123)
75. Braun, J. M.; Yolton, K.; Dietrich, K. N.; Hornung, R.; Ye, X.; Calafat, A. M.; Lanphear, B. P. Prenatal bisphenol A exposure and early childhood behavior. Environ. Health. Perspect., 2009, 117(12), 12-1952.
76. Dallinga, J. W.; Moonen, E. J.; Dumoulin, J. C.; Evers, J. L.; Geraedts, J. P.; Kleinjans, J. C. Decreased human semen quality and organochlorine compounds in blood. Hum. Reprod., 2002, 17(8), 8-1979.
77. Irvine, D. S. Declining sperm quality: a review of facts and hypotheses. Baillieres Clin. Obstet. Gynaecol., 1997, 11(4), 4-671.
78. Golden, R. J.; Noller, K. L.; Titus-Ernstoff, L.; Kaufman, R. H.; Mittendorf, R.; Stillman, R.; Reese, E. A. Environmental endocrine modulators and human health: an assessment of the biological evidence. Crit. Rev. Toxicol., 1998, 28(2), 2-227.
79. Izzotti, A.; Longobardi, M.; Cartiglia, C.; D'Agostini, F.; Kanitz, S.; De Flora, S. Pharmacological modulation of genome and proteome alterations in mice treated with the endocrine disruptor bisphenol A. Curr. Cancer Drug Targets, 2010, 10(2), 2-154.
80. Izzotti, A.; Kanitz, S.; D'Agostini, F.; Camoirano, A.; De Flora, S. Formation of adducts by bisphenol A, an endocrine disruptor, in DNA in vitro and in liver and mammary tissue of mice. Mutat. Res., 2009, 679(1-2), 28-32.
81. Blair, R. M.; Fang, H.; Branham, W. S.; Hass, B. S.; Dial, S. L.; Moland, C. L.; Tong, W.; Shi, L.; Perkins, R.; Sheehan, D. M. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol. Sci., 2000, 54(1), 1-153.
82. Kroll, G. The "Silent Springs" of Rachel Carson: mass media and the origins of modern environmentalism. Public Underst. Sci., 2001, 10(4), 4-420.
83. Coyle, Y. M. The effect of environment on breast cancer risk. Breast Cancer Res. Treat., 2004, 84(3), 3-288.
84. Folmar, L. C.; Hemmer, M.; Denslow, N. D.; Kroll, K.; Chen, J.; Cheek, A.; Richman, H.; Meredith, H.; Grau, E. G. A comparison of the estrogenic potencies of estradiol, ethynylestradiol, diethylstilbestrol, nonylphenol and methoxychlor in vivo and in vitro. Aquat. Toxicol., 2002, 60(1-2), 101-110. (Pubitemid 36153016)
85. Vandenberg, L. N.; Colborn, T.; Hayes, T. B.; Heindel, J. J.; Jacobs, D. R., Jr.; Lee, D. H.; Shioda, T.; Soto, A. M.; vom Saal, F. S.; Welshons, W. V.; Zoeller, R. T.; Myers, J. P. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr. Rev., 2012, 33(3), 3-455.
86. Baker, M. E. Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors. Mol. Cell. Endocrinol., 2004, 215(1-2), 55-62. (Pubitemid 38333243)
87. Soto, A. M.; Sonnenschein, C.; Chung, K. L.; Fernandez, M. F.; Olea, N.; Serrano, F. O. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ. Health Perspect., 1995, 103(7), 7-122.
88. Blom, A.; Ekman, E.; Johannisson, A.; Norrgren, L.; Pesonen, M. Effects of xenoestrogenic environmental pollutants on the proliferation of a human breast cancer cell line (MCF-7). Arch. Environ. Contam. Toxicol., 1998, 34(3), 3-310.
89. Filardo, E. J.; Quinn, J. A.; Bland, K. I.; Frackelton, A. R., Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol., 2000, 14(10), 10-1660.
90. Filardo, E. J.; Quinn, J. A.; Frackelton, A. R., Jr.; Bland, K. I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol., 2002, 16(1), 1-84.
91. Carmeci, C.; Thompson, D. A.; Ring, H. Z.; Francke, U.; Weigel, R. J. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics, 1997, 45(3), 3-617.
92. Maggiolini, M.; Vivacqua, A.; Fasanella, G.; Recchia, A. G.; Sisci, D.; Pezzi, V.; Montanaro, D.; Musti, A. M.; Picard, D.; Ando, S. The G protein-coupled receptor GPR30 mediates c-fos upregulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem., 2004, 279(26), 26-27016.
93. Vivacqua, A.; Bonofiglio, D.; Recchia, A. G.; Musti, A. M.; Picard, D.; Ando, S.; Maggiolini, M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17betaestradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol., 2006, 20(3), 3-646.
94. Revankar, C. M.; Cimino, D. F.; Sklar, L. A.; Arterburn, J. B.; Prossnitz, E. R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307(5715), 5715-1630.
95. Marino, M.; Pellegrini, M.; La Rosa, P.; Acconcia, F. Susceptibility of estrogen receptor rapid responses to xenoestrogens: Physiological outcomes. Steroids, 2012, 77(10), 10-917.
96. Cicatiello, L.; Scafoglio, C.; Altucci, L.; Cancemi, M.; Natoli, G.; Facchiano, A.; Iazzetti, G.; Calogero, R.; Biglia, N.; De Bortoli, M.; Sfiligoi, C.; Sismondi, P.; Bresciani, F.; Weisz, A. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 2004, 32 (3)
97. Terasaka, S.; Inoue, A.; Tanji, M.; Kiyama, R., Expression profiling of estrogen-responsive genes in breast cancer cells treated with alkylphenols, chlorinated phenols, parabens, or bis- and benzoylphenols for evaluation of estrogenic activity. Toxicol. Lett., 2006, 163(2), 130-141.
98. Inoue, A.; Seino, Y.; Terasaka, S.; Hayashi, S.; Yamori, T.; Tanji, M.; Kiyama, R. Comparative profiling of the gene expression for estrogen responsiveness in cultured human cell lines. Toxicol. In Vitro, 2007, 21(4), 4-752.
99. Inoue, A.; Yoshida, N.; Omoto, Y.; Oguchi, S.; Yamori, T.; Kiyama, R.; Hayashi, S. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J. Mol. Endocrinol., 2002, 29(2), 2-192.
100. Terasaka, S.; Aita, Y.; Inoue, A.; Hayashi, S.; Nishigaki, M.; Aoyagi, K.; Sasaki, H.; Wada-Kiyama, Y.; Sakuma, Y.; Akaba, S.; Tanaka, J.; Sone, H.; Yonemoto, J.; Tanji, M.; Kiyama, R. Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ. Health Perspect., 2004, 112(7), 7-781.
101. Amaro, A. A.; Esposito, A. I.; Mirisola, V.; Mehilli, A.; Rosano, C.; Noonan, D. M.; Albini, A.; Pfeffer, U.; Angelini, G. Endocrine disruptor agent Nonyl phenol exerts an estrogen-like transcriptional activity on estrogen receptor positive breast cancer cells. Curr. Med. Chem., 2013. [Epub ahead of print].
102. Lee, P. C.; Lee, W. In vivo estrogenic action of nonylphenol in immature female rats. Bull. Environ. Contam. Toxicol., 1996, 57(3), 3-348.
103. Anway, M. D.; Cupp, A. S.; Uzumcu, M.; Skinner, M. K. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science, 2005, 308(5727), 5727-1469.
104. Hunt, P. A.; Susiarjo, M.; Rubio, C.; Hassold, T. J. The bisphenol A experience: a primer for the analysis of environmental effects on mammalian reproduction. Biol. Reprod., 2009, 81(5), 5-813.
105. George, O.; Bryant, B. K.; Chinnasamy, R.; Corona, C.; Arterburn, J. B.; Shuster, C. B. Bisphenol A directly targets tubulin to disrupt spindle organization in embryonic and somatic cells. ACS Chem. Biol., 2008, 3(3), 3-179.
106. Eichenlaub-Ritter, U.; Vogt, E.; Cukurcam, S.; Sun, F.; Pacchierotti, F.; Parry, J. Exposure of mouse oocytes to bisphenol A causes meiotic arrest but not aneuploidy. Mutat. Res., 2008, 651(1-2), 82-92.
107. Jung, E. M.; Choi, K. C.; Yu, F. H.; Jeung, E. B. Effects of 17betaestradiol and xenoestrogens on mouse embryonic stem cells. Toxicol. In Vitro, 2010, 24(6), 6-1545.
108. Galluzzo, P.; Rastelli, C.; Bulzomi, P.; Acconcia, F.; Pallottini, V.; Marino, M. 17beta-Estradiol regulates the first steps of skeletal muscle cell differentiation via ER-alpha-mediated signals. Am. J. Physiol. Cell Physiol., 2009, 297(5), C1249-C1262.
109. Fenton, S. E. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology, 2006, 147(6), S18-S24. (Pubitemid 43764586)
110. Moon, H. J.; Han, S. Y.; Shin, J. H.; Kang, I. H.; Kim, T. S.; Hong, J. H.; Kim, S. H.; Fenton, S. E. Gestational exposure to nonylphenol causes precocious mammary gland development in female rat offspring. J. Reprod. Dev., 2007, 53(2), 2-344.
111. Russo, J.; Russo, I. H. Biological and molecular bases of mammary carcinogenesis. Lab. Invest., 1987, 57(2), 2-137.
112. Vogel, V. G. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev. Anticancer Ther., 2009, 9(1), 1-60.
113. Katalinic, A.; Rawal, R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res. Treat., 2008, 107(3), 3-430.
114. Hinrichs, B.; Zahid, M.; Saeed, M.; Ali, M. F.; Cavalieri, E. L.; Rogan, E. G. Formation of diethylstilbestrol-DNA adducts in human breast epithelial cells and inhibition by resveratrol. J. Steroid Biochem. Mol. Biol., 2011, 127(3-5), 276-281.
115. Tsubura, A.; Uehara, N.; Matsuoka, Y.; Yoshizawa, K.; Yuri, T. Estrogen and progesterone treatment mimicking pregnancy for protection from breast cancer. In Vivo, 2008, 22(2), 2-201.
116. Dey, S.; Soliman, A. S.; Hablas, A.; Seifeldin, I. A.; Ismail, K.; Ramadan, M.; El-Hamzawy, H.; Wilson, M. L.; Banerjee, M.; Boffetta, P.; Harford, J.; Merajver, S. D. Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. Breast Cancer Res. Treat., 2010, 120(1), 1-160.
117. Dey, S.; Soliman, A. S.; Merajver, S. D. Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. Med. Hypotheses, 2009, 72(6), 6-656.
118. McPherson, K.; Steel, C. M.; Dixon, J. M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ, 2000, 321(7261), 7261-628.
119. Mitra, A. K.; Faruque, F. S.; Avis, A. L. Breast cancer and environmental risks: where is the link? J. Environ. Health, 2004, 66(7), 7-32.
120. Vivacqua, A.; Recchia, A. G.; Fasanella, G.; Gabriele, S.; Carpino, A.; Rago, V.; Di Gioia, M. L.; Leggio, A.; Bonofiglio, D.; Liguori, A.; Maggiolini, M. The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. Endocrine, 2003, 22(3), 3-284.
121. Hess-Wilson, J. K.; Boldison, J.; Weaver, K. E.; Knudsen, K. E. Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis. Breast Cancer Res. Treat., 2006, 96(3), 3-292.
122. Jenkins, S.; Betancourt, A. M.; Wang, J.; Lamartiniere, C. A. Endocrine-active chemicals in mammary cancer causation and prevention. J. Steroid Biochem. Mol. Biol., 2012, 129(3-5), 191-200.
123. Davis, S. R. Phytoestrogen therapy for menopausal symptoms? BMJ., 2001, 323(7309), 7309-355.
124. Tice, J. A.; Ettinger, B.; Ensrud, K.; Wallace, R.; Blackwell, T.; Cummings, S. R. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA, 2003, 290(2), 2-214.
125. Bar-El, D. S.; Reifen, R. Soy as an endocrine disruptor: cause for caution? J. Pediatr. Endocrinol. Metab., 2010, 23(9), 9-861.
126. Bedell, S.; Nachtigall, M.; Naftolin, F. The pros and cons of plant estrogens for menopause. J. Steroid Biochem. Mol. Biol., 2012. [Epub ahead of print].
127. Martin, P. M.; Horwitz, K. B.; Ryan, D. S.; McGuire, W. L. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology, 1978, 103(5), 5-1867.
128. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 1997, 138(3), 3-870.
129. Sotoca, A. M.; Ratman, D.; van der Saag, P.; Strom, A.; Gustafsson, J. A.; Vervoort, J.; Rietjens, I. M.; Murk, A. J. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio. J. Steroid Biochem. Mol. Biol., 2008, 112(4-5), 171-178.
130. Setchell, K. D.; Brown, N. M.; Desai, P. B.; Zimmer-Nechimias, L.; Wolfe, B.; Jakate, A. S.; Creutzinger, V.; Heubi, J. E. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J. Nutr., 2003, 133(4), 4-1035.
131. Rozman, K. K.; Bhatia, J.; Calafat, A. M.; Chambers, C.; Culty, M.; Etzel, R. A.; Flaws, J. A.; Hansen, D. K.; Hoyer, P. B.; Jeffery, E. H.; Kesner, J. S.; Marty, S.; Thomas, J. A.; Umbach, D. NTP-CERHR expert panel report on the reproductive and developmental toxicity of genistein. Birth Defects Res. B Dev. Reprod. Toxicol., 2006, 77(6), 6-638.
132. Duffy, C.; Perez, K.; Partridge, A. Implications of phytoestrogen intake for breast cancer. CA Cancer J. Clin., 2007, 57(5), 5-277.
133. Pruthi, S.; Qin, R.; Terstreip, S. A.; Liu, H.; Loprinzi, C. L.; Shah, T. R.; Tucker, K. F.; Dakhil, S. R.; Bury, M. J.; Carolla, R. L.; Steen, P. D.; Vuky, J.; Barton, D. L. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause, 2012, 19(1), 1-53.
134. Takemura, H.; Sakakibara, H.; Yamazaki, S.; Shimoi, K. Breast cancer and flavonoids - A role in prevention. Curr. Pharm. Des., 2013. [Epub ahead of print].
135. Sammartino, A.; Tommaselli, G. A.; Gargano, V.; di Carlo, C.; Attianese, W.; Nappi, C. Short-term effects of a combination of isoflavones, lignans and Cimicifuga racemosa on climactericrelated symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled trial. Gynecol. Endocrinol., 2006, 22(11), 11-650.
136. Pawlak, M.; Lefebvre, P.; Staels, B. General molecular biology and architecture of nuclear receptors. Curr. Top. Med. Chem., 2012, 12(6), 6-504.
137. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett., 1996, 392(1), 1-53.
138. Ogawa, S.; Inoue, S.; Watanabe, T.; Hiroi, H.; Orimo, A.; Hosoi, T.; Ouchi, Y.; Muramatsu, M. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem. Biophys. Res. Commun., 1998, 243(1), 1-126.
139. Gosden, J. R.; Middleton, P. G.; Rout, D. Localization of the human oestrogen receptor gene to chromosome 6q24-q27 by in situ hybridization. Cytogenet. Cell Genet., 1986, 43(3-4), 218-220. (Pubitemid 17234630)
140. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjold, M.; Gustafsson, J. A. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab., 1997, 82(12), 12-4265.
141. Hawkins, M. B.; Thornton, J. W.; Crews, D.; Skipper, J. K.; Dotte, A.; Thomas, P. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc. Natl. Acad. Sci. U S A, 2000, 97(20), 20-10756.
142. Giguere, V.; Yang, N.; Segui, P.; Evans, R. M. Identification of a new class of steroid hormone receptors. Nature, 1988, 331(6151), 6151-94.
143. Kumar, R.; Thompson, E. B. The structure of the nuclear hormone receptors. Steroids, 1999, 64(5), 5-319.
144. McEwan, I. J. Sex, drugs and gene expression: signalling by members of the nuclear receptor superfamily. Essays Biochem., 2004, 40, 1-10. (Pubitemid 38901164)
145. Schwabe, J. W.; Neuhaus, D.; Rhodes, D. Solution structure of the DNA-binding domain of the oestrogen receptor. Nature, 1990, 348(6300), 6300-461.
146. Schwabe, J. W.; Chapman, L.; Finch, J. T.; Rhodes, D. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell, 1993, 75(3), 3-578.
147. Schwabe, J. W.; Chapman, L.; Finch, J. T.; Rhodes, D.; Neuhaus, D. DNA recognition by the oestrogen receptor: from solution to the crystal. Structure, 1993, 1(3), 3-204.
148. Schwabe, J. W.; Chapman, L.; Rhodes, D. The oestrogen receptor recognizes an imperfectly palindromic response element through an alternative side-chain conformation. Structure, 1995, 3(2), 2-213.
149. Rosano, C.; Stec-Martyna, E.; Lappano, R.; Maggiolini, M. Structure-based approach for the discovery of novel selective estrogen receptor modulators. Curr. Med. Chem., 2011, 18(8), 8-1194.
150. Pratt, W. B.; Galigniana, M. D.; Morishima, Y.; Murphy, P. J. Role of molecular chaperones in steroid receptor action. Essays Biochem., 2004, 40, 41-58. (Pubitemid 38901166)
151. Matthews, J.; Gustafsson, J. A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv., 2003, 3(5), 281-292.
152. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E. A structural biologist's view of the oestrogen receptor. J. Steroid Biochem. Mol. Biol., 2000, 74(5), 5-268.
153. Pfeffer, U.; Fecarotta, E.; Vidali, G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res., 1995, 55(10), 10-2165.
154. Ferro, P.; Forlani, A.; Muselli, M.; Pfeffer, U. Alternative splicing of the human estrogen receptor alpha primary transcript: mechanisms of exon skipping. Int. J. Mol. Med., 2003, 12(3), 3-363.
155. Pfeffer, U.; Fecarotta, E.; Castagnetta, L.; Vidali, G. Estrogen receptor variant messenger RNA lacking exon 4 in estrogenresponsive human breast cancer cell lines. Cancer Res., 1993, 53(4), 4-743.
156. Lappano, R.; Rosano, C.; Madeo, A.; Albanito, L.; Plastina, P.; Gabriele, B.; Forti, L.; Stivala, L. A.; Iacopetta, D.; Dolce, V.; Ando, S.; Pezzi, V.; Maggiolini, M. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food Res., 2009, 53(7), 7-858.
157. Martin-Santamaria, S.; Rodriguez, J. J.; de Pascual-Teresa, S.; Gordon, S.; Bengtsson, M.; Garrido-Laguna, I.; Rubio-Viqueira, B.; Lopez-Casas, P. P.; Hidalgo, M.; de Pascual-Teresa, B.; Ramos, A. New scaffolds for the design of selective estrogen receptor modulators. Org. Biomol. Chem., 2008, 6(19), 19-3496.
158. Manas, E. S.; Xu, Z. B.; Unwalla, R. J.; Somers, W. S. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Structure, 2004, 12(12), 12-2207.
159. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 1998, 95(7), 7-937.
160. Vajdos, F. F.; Hoth, L. R.; Geoghegan, K. F.; Simons, S. P.; Le Motte, P. K.; Danley, D. E.; Ammirati, M. J.; Pandit, J. The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene. Protein Sci., 2007, 16(5), 5-905.
161. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J. E.; McKee, D. D.; Galardi, C. M.; Plunket, K. D.; Nolte, R. T.; Parks, D. J.; Moore, J. T.; Kliewer, S. A.; Willson, T. M.; Stimmel, J. B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature, 2002, 415(6873), 6873-817.
162. Mak, P.; Leung, Y. K.; Tang, W. Y.; Harwood, C.; Ho, S. M. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia, 2006, 8(11), 11-904.
163. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J. A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J., 1999, 18(17), 17-4618.
164. Sotoca, A. M.; Gelpke, M. D.; Boeren, S.; Strom, A.; Gustafsson, J. A.; Murk, A. J.; Rietjens, I. M.; Vervoort, J. Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol. Cell. Proteomics, 2011, 10(1), M110 002170.
165. Ho, S. M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem., 2004, 91(3), 3-503.
166. Mueller, S. O. Overview of in vitro tools to assess the estrogenic and antiestrogenic activity of phytoestrogens. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 777(1-2), 155-165. (Pubitemid 35264606)
167. Marik, R.; Allu, M.; Anchoori, R.; Stearns, V.; Umbricht, C. B.; Khan, S. Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer. Cancer Biol. Ther., 2011, 11(10), 10-892.
168. Routledge, E. J.; White, R.; Parker, M. G.; Sumpter, J. P. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J. Biol. Chem., 2000, 275(46), 46-35993.
169. Cappelletti, V.; Saturno, G.; Miodini, P.; Korner, W.; Daidone, M. G. Selective modulation of ER-beta by estradiol and xenoestrogens in human breast cancer cell lines. Cell. Mol. Life Sci., 2003, 60(3), 3-576.
170. Pennie, W. D.; Aldridge, T. C.; Brooks, A. N. Differential activation by xenoestrogens of ER alpha and ER beta when linked to different response elements. J. Endocrinol., 1998, 158(3), R11-14. (Pubitemid 28407555)
171. Szego, C. M.; Davis, J. S. Adenosine 3', 5'-monophosphate in rat uterus: acute elevation by estrogen. Proc. Natl. Acad. Sci. U S A, 1967, 58(4), 4-1718.
172. Ho, K. J.; Liao, J. K. Non-nuclear actions of estrogen: new targets for prevention and treatment of cardiovascular disease. Mol. Interv., 2002, 2(4), 4-228.
173. Kelly, M. J.; Levin, E. R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab., 2001, 12(4), 4-156.
174. Levin, E. R. Cell localization, physiology, and nongenomic actions of estrogen receptors. J. Appl. Physiol., 2001, 91(4), 4-1867.
175. Levin, E. R. Cellular functions of plasma membrane estrogen receptors. Steroids, 2002, 67(6), 6-475.
176. Razandi, M.; Pedram, A.; Park, S. T.; Levin, E. R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem., 2003, 278(4), 4-2712.
177. Hall, J. M.; Couse, J. F.; Korach, K. S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem., 2001, 276(40), 40-36872.
178. Acconcia, F.; Ascenzi, P.; Fabozzi, G.; Visca, P.; Marino, M. S-palmitoylation modulates human estrogen receptor-alpha functions. Biochem. Biophys. Res. Commun., 2004, 316(3), 3-883.
179. Li, K. M.; Todorovic, R.; Devanesan, P.; Higginbotham, S.; Kofeler, H.; Ramanathan, R.; Gross, M. L.; Rogan, E. G.; Cavalieri, E. L. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3, 4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis, 2004, 25(2), 2-297.
180. Navarro, C. E.; Saeed, S. A.; Murdock, C.; Martinez-Fuentes, A. J.; Arora, K. K.; Krsmanovic, L. Z.; Catt, K. J. Regulation of cyclic adenosine 3', 5'-monophosphate signaling and pulsatile neurosecretion by Gi-coupled plasma membrane estrogen receptors in immortalized gonadotrophin-releasing hormone neurons. Mol. Endocrinol., 2003, 17(12), 12-1804.
181. Wyckoff, M. H.; Chambliss, K. L.; Mineo, C.; Yuhanna, I. S.; Mendelsohn, M. E.; Mumby, S. M.; Shaul, P. W. Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha (i). J. Biol. Chem., 2001, 276(29), 29-27076.
182. Takada, Y.; Kato, C.; Kondo, S.; Korenaga, R.; Ando, J. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun., 1997, 240(3), 3-741.
183. Gobeil, F.; Fortier, A.; Zhu, T.; Bossolasco, M.; Leduc, M.; Grandbois, M.; Heveker, N.; Bkaily, G.; Chemtob, S.; Barbaz, D. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can. J. Physiol. Pharmacol., 2006, 84(3-4), 287-297. (Pubitemid 44481092)
184. Funakoshi, T.; Yanai, A.; Shinoda, K.; Kawano, M. M.; Mizukami, Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem. Biophys. Res. Commun., 2006, 346(3), 3-910.
185. Thomas, P.; Pang, Y.; Filardo, E. J.; Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology, 2005, 146(2), 2-632.
186. Lappano, R.; Santolla, M. F.; Pupo, M.; Sinicropi, M. S.; Caruso, A.; Rosano, C.; Maggiolini, M. MIBE acts as antagonist ligand of both estrogen receptor alpha and GPER in breast cancer cells. Breast Cancer Res., 2012, 14(1), R12.
187. Dennis, M. K.; Burai, R.; Ramesh, C.; Petrie, W. K.; Alcon, S. N.; Nayak, T. K.; Bologa, C. G.; Leitao, A.; Brailoiu, E.; Deliu, E.; Dun, N. J.; Sklar, L. A.; Hathaway, H. J.; Arterburn, J. B.; Oprea, T. I.; Prossnitz, E. R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol., 2009, 5(6), 6-427.
188. Dennis, M. K.; Field, A. S.; Burai, R.; Ramesh, C.; Petrie, W. K.; Bologa, C. G.; Oprea, T. I.; Yamaguchi, Y.; Hayashi, S.; Sklar, L. A.; Hathaway, H. J.; Arterburn, J. B.; Prossnitz, E. R. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J. Steroid Biochem. Mol. Biol., 2011, 127(3-5), 358-366.
189. Rosano, C.; Lappano, R.; Santolla, M. F.; Ponassi, M.; Donadini, A.; Maggiolini, M. Recent advances in the rationale design of GPER ligands. Curr. Med. Chem., 2012, 19(36), 36-6206.
190. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289(5480), 5480-745.
191. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature, 2007, 450(7168), 383-387. (Pubitemid 350126755)
192. Kim, D. E.; Chivian, D.; Baker, D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res., 2004, 32, W526-W531. (Pubitemid 38997389)
193. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol., 1993, 234(3), 3-815.
194. Pupo, M.; Pisano, A.; Lappano, R.; Santolla, M. F.; De Francesco, E. M.; Abonante, S.; Rosano, C.; Maggiolini, M. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ. Health Perspect., 2012, 120(8), 8-1182.
195. Lappano, R.; Rosano, C.; Santolla, M. F.; Pupo, M.; De Francesco, E. M.; De Marco, P.; Ponassi, M.; Spallarossa, A.; Ranise, A.; Maggiolini, M. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr. Cancer Drug Targets, 2012, 12(5), 5-542.
196. Lappano, R.; Rosano, C.; De Marco, P.; De Francesco, E. M.; Pezzi, V.; Maggiolini, M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell. Endocrinol., 2010, 320(1-2), 162-170.
197. Yohannan, S.; Faham, S.; Yang, D.; Whitelegge, J. P.; Bowie, J. U. The evolution of transmembrane helix kinks and the structural diversity of G protein-coupled receptors. Proc. Natl. Acad. Sci. USA., 2004, 101(4), 4-963.
198. Prossnitz, E. R.; Arterburn, J. B.; Smith, H. O.; Oprea, T. I.; Sklar, L. A.; Hathaway, H. J. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu. Rev. Physiol., 2008, 70, 165-190. (Pubitemid 351738176)
199. Prossnitz, E. R.; Sklar, L. A.; Oprea, T. I.; Arterburn, J. B. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol. Sci., 2008, 29(3), 3-123.
200. Maggiolini, M.; Picard, D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J. Endocrinol., 2010, 204(2), 2-114.
201. Filardo, E. J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J. Steroid Biochem. Mol. Biol., 2002, 80(2), 2-238.
202. Prossnitz, E. R.; Maggiolini, M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell. Endocrinol., 2009, 308(1-2), 32-38.
203. Albanito, L.; Lappano, R.; Madeo, A.; Chimento, A.; Prossnitz, E. R.; Cappello, A. R.; Dolce, V.; Abonante, S.; Pezzi, V.; Maggiolini, M. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect., 2008, 116(12), 12-1655.
204. Vivacqua, A.; Lappano, R.; De Marco, P.; Sisci, D.; Aquila, S.; De Amicis, F.; Fuqua, S. A.; Ando, S.; Maggiolini, M. G proteincoupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol. Endocrinol., 2009, 23(11), 11-1826.